Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
企業コードINDV
会社名Indivior PLC
上場日Dec 24, 2014
最高経営責任者「CEO」Ciaffoni (Joseph J)
従業員数1030
証券種類Ordinary Share
決算期末Dec 24
本社所在地234 Bath Road
都市SLOUGH
証券取引所NASDAQ OMX - NASDAQ BASIC
国United Kingdom
郵便番号SL1 4EE
電話番号448043791090
ウェブサイトhttps://www.indivior.com/en
企業コードINDV
上場日Dec 24, 2014
最高経営責任者「CEO」Ciaffoni (Joseph J)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし